Global Non-Insulin Therapies for Diabetes Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Non-Insulin Therapies for Diabetes Revenue
• 1.4 Market by Type
  • 1.4.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Alpha-glucosidase Inhibitors
  • 1.4.3 Amylin Agonists
  • 1.4.4 Biguanides
  • 1.4.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
  • 1.4.6 Glinides / Meglitinides
  • 1.4.7 GLP-1 Analogs / GLP-1 Agonists
  • 1.4.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
  • 1.4.9 Sulfonylureas
  • 1.4.10 Thiazolidinediones
  • 1.4.11 Others
• 1.5 Market by Application
  • 1.5.1 Global Non-Insulin Therapies for Diabetes Market Share by Application: 2020 VS 2026
  • 1.5.2 Monitoring
  • 1.5.3 Diagnosis
  • 1.5.4 Treatment
  • 1.5.5 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Non-Insulin Therapies for Diabetes Market Perspective (2015-2026)
• 2.2 Global Non-Insulin Therapies for Diabetes Growth Trends by Regions
  • 2.2.1 Non-Insulin Therapies for Diabetes Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Non-Insulin Therapies for Diabetes Historic Market Share by Regions (2015-2020)
  • 2.2.3 Non-Insulin Therapies for Diabetes Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Non-Insulin Therapies for Diabetes Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Non-Insulin Therapies for Diabetes Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Non-Insulin Therapies for Diabetes Players by Market Size
  • 3.1.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue (2015-2020)
  • 3.1.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio
  • 3.2.1 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Non-Insulin Therapies for Diabetes Revenue in 2019
• 3.3 Non-Insulin Therapies for Diabetes Key Players Head office and Area Served
• 3.4 Key Players Non-Insulin Therapies for Diabetes Product Solution and Service
• 3.5 Date of Enter into Non-Insulin Therapies for Diabetes Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Type (2015-2020)
• 4.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
• 5.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Non-Insulin Therapies for Diabetes Market Size (2015-2020)
• 6.2 Non-Insulin Therapies for Diabetes Key Players in North America (2019-2020)
• 6.3 North America Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
• 6.4 North America Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Non-Insulin Therapies for Diabetes Market Size (2015-2020)
• 7.2 Non-Insulin Therapies for Diabetes Key Players in Europe (2019-2020)
• 7.3 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
• 7.4 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)

8 China

• 8.1 China Non-Insulin Therapies for Diabetes Market Size (2015-2020)
• 8.2 Non-Insulin Therapies for Diabetes Key Players in China (2019-2020)
• 8.3 China Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
• 8.4 China Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Non-Insulin Therapies for Diabetes Market Size (2015-2020)
• 9.2 Non-Insulin Therapies for Diabetes Key Players in Japan (2019-2020)
• 9.3 Japan Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
• 9.4 Japan Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Non-Insulin Therapies for Diabetes Market Size (2015-2020)
• 10.2 Non-Insulin Therapies for Diabetes Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
• 10.4 Southeast Asia Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)

11 India

• 11.1 India Non-Insulin Therapies for Diabetes Market Size (2015-2020)
• 11.2 Non-Insulin Therapies for Diabetes Key Players in India (2019-2020)
• 11.3 India Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
• 11.4 India Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Non-Insulin Therapies for Diabetes Market Size (2015-2020)
• 12.2 Non-Insulin Therapies for Diabetes Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
• 12.4 Central & South America Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 GSK
  • 13.1.1 GSK Company Details
  • 13.1.2 GSK Business Overview
  • 13.1.3 GSK Non-Insulin Therapies for Diabetes Introduction
  • 13.1.4 GSK Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020))
  • 13.1.5 GSK Recent Development
• 13.2 Eli Lilly
  • 13.2.1 Eli Lilly Company Details
  • 13.2.2 Eli Lilly Business Overview
  • 13.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Introduction
  • 13.2.4 Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 13.2.5 Eli Lilly Recent Development
• 13.3 Sumitomo Dainippon Pharma
  • 13.3.1 Sumitomo Dainippon Pharma Company Details
  • 13.3.2 Sumitomo Dainippon Pharma Business Overview
  • 13.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Introduction
  • 13.3.4 Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 13.3.5 Sumitomo Dainippon Pharma Recent Development
• 13.4 Intarcia Therapeutics
  • 13.4.1 Intarcia Therapeutics Company Details
  • 13.4.2 Intarcia Therapeutics Business Overview
  • 13.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Introduction
  • 13.4.4 Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 13.4.5 Intarcia Therapeutics Recent Development
• 13.5 Servier
  • 13.5.1 Servier Company Details
  • 13.5.2 Servier Business Overview
  • 13.5.3 Servier Non-Insulin Therapies for Diabetes Introduction
  • 13.5.4 Servier Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 13.5.5 Servier Recent Development
• 13.6 Pfizer
  • 13.6.1 Pfizer Company Details
  • 13.6.2 Pfizer Business Overview
  • 13.6.3 Pfizer Non-Insulin Therapies for Diabetes Introduction
  • 13.6.4 Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 13.6.5 Pfizer Recent Development
• 13.7 Merck
  • 13.7.1 Merck Company Details
  • 13.7.2 Merck Business Overview
  • 13.7.3 Merck Non-Insulin Therapies for Diabetes Introduction
  • 13.7.4 Merck Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 13.7.5 Merck Recent Development
• 13.8 Dong-A Pharmaceutical
  • 13.8.1 Dong-A Pharmaceutical Company Details
  • 13.8.2 Dong-A Pharmaceutical Business Overview
  • 13.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
  • 13.8.4 Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 13.8.5 Dong-A Pharmaceutical Recent Development
• 13.9 Luye Pharma Group
  • 13.9.1 Luye Pharma Group Company Details
  • 13.9.2 Luye Pharma Group Business Overview
  • 13.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Introduction
  • 13.9.4 Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 13.9.5 Luye Pharma Group Recent Development
• 13.10 Eurofarma
  • 13.10.1 Eurofarma Company Details
  • 13.10.2 Eurofarma Business Overview
  • 13.10.3 Eurofarma Non-Insulin Therapies for Diabetes Introduction
  • 13.10.4 Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 13.10.5 Eurofarma Recent Development
• 13.11 Geropharm
  • 10.11.1 Geropharm Company Details
  • 10.11.2 Geropharm Business Overview
  • 10.11.3 Geropharm Non-Insulin Therapies for Diabetes Introduction
  • 10.11.4 Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 10.11.5 Geropharm Recent Development
• 13.12 Alkem Labs
  • 10.12.1 Alkem Labs Company Details
  • 10.12.2 Alkem Labs Business Overview
  • 10.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Introduction
  • 10.12.4 Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 10.12.5 Alkem Labs Recent Development
• 13.13 SatRx
  • 10.13.1 SatRx Company Details
  • 10.13.2 SatRx Business Overview
  • 10.13.3 SatRx Non-Insulin Therapies for Diabetes Introduction
  • 10.13.4 SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 10.13.5 SatRx Recent Development
• 13.14 Jiangsu Hansoh Pharmaceutical
  • 10.14.1 Jiangsu Hansoh Pharmaceutical Company Details
  • 10.14.2 Jiangsu Hansoh Pharmaceutical Business Overview
  • 10.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Introduction
  • 10.14.4 Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 10.14.5 Jiangsu Hansoh Pharmaceutical Recent Development
• 13.15 Novo Nordisk
  • 10.15.1 Novo Nordisk Company Details
  • 10.15.2 Novo Nordisk Business Overview
  • 10.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Introduction
  • 10.15.4 Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 10.15.5 Novo Nordisk Recent Development
• 13.16 Emisphere
  • 10.16.1 Emisphere Company Details
  • 10.16.2 Emisphere Business Overview
  • 10.16.3 Emisphere Non-Insulin Therapies for Diabetes Introduction
  • 10.16.4 Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 10.16.5 Emisphere Recent Development
• 13.17 Uni-Bio Science Group
  • 10.17.1 Uni-Bio Science Group Company Details
  • 10.17.2 Uni-Bio Science Group Business Overview
  • 10.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Introduction
  • 10.17.4 Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 10.17.5 Uni-Bio Science Group Recent Development
• 13.18 Takeda
  • 10.18.1 Takeda Company Details
  • 10.18.2 Takeda Business Overview
  • 10.18.3 Takeda Non-Insulin Therapies for Diabetes Introduction
  • 10.18.4 Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 10.18.5 Takeda Recent Development
• 13.19 3SBio
  • 10.19.1 3SBio Company Details
  • 10.19.2 3SBio Business Overview
  • 10.19.3 3SBio Non-Insulin Therapies for Diabetes Introduction
  • 10.19.4 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 10.19.5 3SBio Recent Development
• 13.20 Jiangsu Hengrui Medicine
  • 10.20.1 Jiangsu Hengrui Medicine Company Details
  • 10.20.2 Jiangsu Hengrui Medicine Business Overview
  • 10.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Introduction
  • 10.20.4 Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2015-2020)
  • 10.20.5 Jiangsu Hengrui Medicine Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer